SGIndia's pharmaceutical industry is preparing for potential disruptions caused by proposed U.S. tariffs on generic drugs under President Donald Trump's administration. The tariffs aim to encourage reshoring of pharmaceutical production to the U.S., with initial zero tariffs for two years followed by steep increases to 100% and then 200%. Analysts warn these measures could affect global drug supply chains, increase medicine costs for Americans, and force Indian manufacturers to reconsider their strategies. India is a major supplier of generic drugs to the U.S., providing nearly half of the generics consumed there. While existing policies on patented and branded drugs remain unaffected due to agreements with global drugmakers, the impact on generic drugs—which rely heavily on international supply chains—is more uncertain. The potential implementation of tariffs on finished medicines rather than raw materials like active pharmaceutical ingredients remains unclear.
Bias read (Center): The article presents the proposed tariffs as a U.S. policy initiative without overtly criticizing or praising the policy. It provides factual information about the potential economic impacts on both the U.S. and India, while avoiding strong ideological framing. The tone remains neutral, focusing on
